Here, we performed a retrospective study to establish optimal clinical cut-off values for serum E2 and FSH as diagnostic markers in discrimination of pre-menopause from postmenopausal status in BC patients, in an attempt to help the oncologists make correct decision to select endocrine therapy drugs for BC patients with unclear menstruation status. Here, BRD2 is linked to breast cancer.